2019 Community Healthcare Professional Supply Chain 
FDA Law Blog
FEBRUARY 16, 2023
sales of naloxone from a wholesale distributor to a harm reduction program) from certain requirements under the Drug Supply Chain Security Act. We previously blogged on FDA’s September 2022 guidance exempting and excluding specific naloxone transactions (e.g.,
BMJ
AUGUST 20, 2021
By John Scott Frazer, Glenn Ross Frazer Reference : Frazer JS , Frazer GR, Analysis of primary care prescription trends in England during the COVID-19 pandemic compared against a predictive model, Family Medicine and Community Health 2021; 9: e001143.
Expert insights. Personalized for you.
64 
Let's personalize your content